Clinical Trial

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-08-01; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2024-10-02
Trial Details
NCT Number NCT06539507
Lead Sponsor BioCryst Pharmaceuticals
Conditions Netherton Syndrome
Enrollment 78 participants
Start Date 2024-09-26
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-16